Nintendo Stock Jumps as Switch 2 Becomes Best-Selling Console in the U.S. in 2025 
ByteDance Finalizes Majority U.S.-Owned TikTok Joint Venture to Avert American Ban 
OpenAI Launches Stargate Community Plan to Offset Energy Costs and Support Local Power Infrastructure 
United Airlines Posts Record Q4 Revenue as Premium Demand Lifts Earnings 
Intel Stock Slides Despite Earnings Beat as Weak Q1 Outlook Raises Concerns 
Global DRAM Chip Shortage Puts Automakers Under New Cost and Supply Pressure 
Ericsson Plans SEK 25 Billion Shareholder Returns as Margins Improve Despite Flat Network Market 
Memory Chip Shortage Drives Higher Gadget Prices and Weakens Global Tech Demand 
Apple China Holiday Sale Offers Discounts Up to 1,000 Yuan on Popular Devices 
JPMorgan and Allen & Company Emerge as Big Winners in Warner Bros Discovery Bidding War 
Valero Makes First Venezuelan Crude Purchase Under New U.S.-Caracas Deal 
Baidu Shares Surge After Official Launch of Advanced Ernie 5.0 AI Model 
Lynas Rare Earths Shares Surge as Quarterly Revenue Jumps on Strong Prices 
FAA Says It Is Not Blocking Boeing 737 MAX 7 and MAX 10 Certification 
BitGo IPO Prices Above Range, Raises $212.8M in Landmark Crypto Market Debut 
Apple Stock Jumps as Company Prepares Major Siri AI Chatbot Upgrade 
Tesla Plans FSD Subscription Price Hikes as Autonomous Capabilities Advance 
ATLANTA, May 03, 2017 -- Alimera Sciences (NASDAQ:ALIM), a leader in research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that it will release its financial results for the first quarter ended March 31, 2017, after the close of the financial markets on May 8, 2017.
An accompanying conference call will be hosted by Dan Myers, Chief Executive Officer and Rick Eiswirth, President and Chief Financial Officer to discuss the results. Management will also be joined by Dr. Christopher Riemann, volunteer professor at the University of Cincinnati department of ophthalmology and member of the board of directors of the Cincinnati Eye Institute to discuss his direct experience with patient outcomes and demand for ILUVIEN. The call will be held at 8:00 AM ET, on Tuesday, May 9, 2017. Please refer to the information below for conference call dial-in information and webcast registration.
Conference Details
Conference date: Tuesday, May 9th, 2017, 8:00 AM ET
Conference dial-in: 877-269-7756
International dial-in: 201-689-7817
Conference Call Name: Alimera Sciences' First Quarter 2017 Results Call
Webcast Registration: Click Here
Following the live call, a replay will be available on the Company's website, www.alimerasciences.com, under "Investor Relations".
About Alimera Sciences
Alimera Sciences, founded in June 2003, is a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals. Alimera is presently focused on diseases affecting the back of the eye, or retina, because these diseases are not well treated with current therapies and will affect millions of people in our aging populations. Alimera’s commitment to retina specialists and their patients is manifest in its product and development portfolio designed to treat early- and late-stage diseases. For more information, please visit www.alimerasciences.com.
Contact: CG Capital 877.889.1972 [email protected]
